



RECEIVED

Express Mail No. _____

Sheet 1 of 3

MAY 15 2002

EXPRESS MAIL NO. EL477036342US

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

26-048

APPLICATION NO.

09/724,620

APPLICANT

Taylor et al.

FILING DATE

November 28, 2000

GROUP

1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAC	AA	5,985,847	11/16/99	Carson et al.			
KAC	AB	6,221,621	4/24/01	Kinders, et al.			
	BY	5,376,356	12/27/94	Morgan, Jr.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KAC	AC	WO 87/06344	10/16/97	PCT				
	AD	WO 9839659	09/11/98	PCT				
	AE	WO 9738136	10/16/97	PCT				
	AF	WO 9637234	11/28/96	PCT				
	AG	EP 0448464	09/25/91	Europe				
	BZ	WO 87/06344	10/22/87	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AH	Castronovo V et al., "Possible role of human natural anti-Gal antibodies in the natural antitumor defense system," J Natl Cancer Inst. 1989 Feb 1;81(3):212-6.
	AI	Clark JI et al., "Natural killer cell-directed bispecific antibodies", in <u>Bispecific Antibodies</u> , Fanger MW (ed.), RG Landis Co., Austin, pp. 77-88.
	AJ	de Gast GC et al., "Clinical perspectives of bispecific antibodies in cancer," Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):121-3.
	AK	Deo et al., 1998, J. of Immunol., 160: 1677 Abstract
	AL	Desai PR et al., "Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection," J Immunol Methods. 1995 Dec 27;188(2):175-85.
	AM	Dodds and Sim (eds.), <u>Complement: A Practical Approach</u> , 1997, Oxford University Press.
	AN	Edberg JC et al., "Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes," J Immunol. 1988 Dec 15;141(12):4258-65.
	AO	Gorter A et al., "Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis," Lab Invest. 1996 Jun;74(6):1039-49.
	AP	Gross DJ et al., "An immunochemical assay for natural IgM antibodies with an affinity to galactose and whose titer is reduced in the sera of cancer patients," Eur J Cancer Clin Oncol. 1988 Mar;24(3):363-7.
	AQ	Hakomori S, "Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism," Cancer Res. 1996 Dec 1;56(23):5309-18.
	AR	Higuchi et al., "Natural humoral immunity in patients with malignant diseases", J Clin Lab Immunol. 1980; 4:141-143.
	AS	Howard and Hughes Jones, 1988, Monoclonal Antibody Therapy, Vol. 45, p. 3
	AT	Irie et al., 1975, "Demonstration of In Vivo Reaction of Anti Body and Complement to Human Cancer Cells by Mixed Hemadsorption", Proc. Amer. Assoc. Cancer Res. Vol 16, p. 170, Abstract
✓	AU	Irie K et al., "Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells," Science. 1974 Nov 1;186(4162):454-6.



MAY 10 2002


Express Mail No. _____

Sheet 2 of 3

TECH CENTER 1600/2900

		Jarvis GA et al., "Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer. 1997 Jun 11;71(6):1049-55.
	AW	Maenpaa A et al., "Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas, "Am J Pathol. 1996 Apr;148(4):1139-52.
	AX	Makrides SC et al., "Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement, "J Biol Chem. 1992 Dec 5;267(34):24754-61.
	AY	Michael et al., "Synthesis of iC3b/C3d and Expression of a CD21-Like Protein by Malignant Epithelium", Growth Factors and Receptors I: Abstract 2167
	AZ	Mehta RL et al., "Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells, "J Immunol. 1986 Mar 1;136(5):1765-71.
	BA	Mollnes TE et al., "Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay, "J Immunol Methods. 1987 Aug 3;101(2):201-7.
	BB	Neri et al., 1983, J. of Gynaecological Oncology, 4:37 Abstract
	BC	Niculescu F et al., "Persistent complement activation on tumor cells in breast cancer, "Am J Pathol. 1992 May;140(5):1039-43.
	BD	Okada H and Baba T, "Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane, "Nature. 1974 Apr 5;248(448):521-2.
	BE	Paul et al., 1993, Immunology, P. 934
	BF	Perlmann et al., 1982, "Interaction of Target Cell-Bound C3bi and C3d With Human Lymphocyte Receptors", J. Exp. Med. 153:1592-1603
	BG	Petronis JD et al., "Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer, "Clin Nucl Med. 1998 Oct;23(10):672-7.
	BH	Reiter et al., 1989, "Killing of Human Tumor Cells by Antibody C3b Conjugates and Human Complement", Targeted Diagn Ther. 2:119-35
	BI	Renner C et al., "Tumor therapy by immune recruitment with bispecific antibodies, "Immunol Rev. 1995 Jun;145:179-209.
	BJ	Schlom et al. 1991, "Monoclonal Antibodies: They're more or less than you think", Molecular Foundations of Oncology, pp. 95-134
	BK	Seegal BC et al., "Immunoglobulins, complement and foreign antigens in human tumor cells, "Int Arch Allergy Appl Immunol. 1976;52(1-4):205-11.
	BL	Segal DM et al., "T-cell targeted cytotoxicity" in <u>Bispecific Antibodies</u> , Fanger MW (ed.), RG Landis Co., Austin, pp. 27-42.
	BM	Springer GF, "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy, "J Mol Med. 1997 Aug;75(8):594-602.
	BN	Springer GF, "T and Tn, general carcinoma autoantigens, "Science. 1984 Jun 15;224(4654):1198-206.
	BO	Tamerius et al., 1985, "Detection of a Neoantigen of Human C3bi and C3d by Monoclonal Antibody", J. of Immunology 135:2015
	BP	Taylor RP et al., "Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor, "Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):152-5.
	BQ	Taylor RP et al., "Quantitative analyses of C3b capture and immune adherence of IgM antibody/dsDNA immune complexes, "J Immunol. 1989 Dec 1;143(11):3626-31.
	BR	Thornton BP et al., "Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells, "Clin Exp Immunol. 1996 Jun;104(3):531-7.
	BS	Taylor et al., 1991, "Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment", Proc. Natl. Acad. Sci. USA 88:3305-3309
	BT	Tosic L et al., "Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose, "J Immunol Methods. 1989 Jun 21;120(2):241-9.
	BU	Vetvicka V et al., "Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules, "Clin Exp Immunol. 1999 Feb;115(2):229-35.

09724620



MAY 15 2002

Express Mail No. _____

Sheet 3 of 3

TECH CENTER 1600/2900

<input checked="" type="checkbox"/>		Vetvicka V et al., "Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18), "J Immunol. 1997 Jul 15;159(2):599-605.
	BW	Vetvicka V et al., "Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, "J Clin Invest. 1996 Jul 1;98(1):50-61.
	BX	Weisman HF et al., "Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis, "Science. 1990 Jul 13;249(4965):146-51.
	CA	Dempsey et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996 Jan 19;271(5247):348-50
	CB	Emery and Harris, Strategies for humanizing antibodies. In <i>Antibody Engineering</i> (2 nd Ed.) Chapter 6, Borrebaeck ed. Oxford University Press, 1995 (pp 159-160 and 180-181 submitted herewith)
	CC	Seya et al. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med. 1990 Dec 1;172(6):1673-80
<input checked="" type="checkbox"/>	CD	Tamerius et al. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody. J Immunol. 1985 Sep;135(3):2015-9

EXAMINER

Karen A. Gamella

DATE CONSIDERED

7/23/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09724620